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Abstract
The off-label use of drugs is one of the most important elements of medical practice and, unfortunately, one that is still 
shrouded in a great deal of controversy and doubt. This is because of a lack of explicit, detailed legal regulations. On 
the one hand, physicians should follow the dosage regimen and indications for use specified in the summary of product 
characteristics (SPC), while on the other hand, for some patients, in particular regarding paediatrics and oncology, there 
may be a lack of therapy that would be characterised for such use as in the SPC. When prescribing off-label therapy, 
doctors must primarily be guided by current medical knowledge and due diligence. Despite the lack of legal regulations, 
several criteria can be distinguished that justify the off-label use of drugs, e.g. the need to save the patient’s life or the 
unsatisfactory result of the therapy recommended to date. Before prescribing a particular drug, the patient should be 
informed, for instance, about the risk of the unregistered use of the medicine. Only after the patient has been properly 
informed can informed consent for treatment be given. A doctor’s failure to satisfy these obligations could expose him 
or her to civil, criminal or disciplinary liability. Polish law also allows for therapy conducted in indications other than 
those arising from the SPC to be publicly financed. Although this requires compliance with the statutory requirements, 
this often constitutes the patient’s key opportunity to actually undergo treatment.
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How to define off-label use
Off-label use in everyday medical practice is a relatively 
common phenomenon. It most frequently arises from the 
experience of doctors. There is no legal definition of off-
-label use. The legal doctrine assumes that it is the use 
of medicinal products in a manner that differs from the 
use specified in the Summary of Product Characteristics 
(SPC) [1]. The SPC is one of the documents required for 
registering a medicinal product so that it can be authorised. 
The information provided in the SPC is presented by the 
Marketing Authorisation Holder (MAH) in the registration 
dossier, and then accepted by the competent authority (i.e. 
in Poland by the Polish Registration Office, URPL).
According to Article 4 of the Act on the Professions of 
Doctor and Dentist [2], a doctor is required to practice the 
profession in accordance with current medical knowledge, 
using methods and measures available to him or her to 
prevent, diagnose and treat diseases, in accordance with 
the principles of professional ethics, and with due care.
As the Supreme Court pointed out in one of its judg-
ments: “The Summary of Product Characteristics (...) is not, 
however, normative, but informative, defining the state of 
knowledge about this agent at a given moment. (...) Due 
to the continuous advancement of medical knowledge, 
a physician must have adequate freedom enabling him 
to use medicines in a manner that is adapted to current 
medical achievements and the needs of the given patient” 
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 — the lack of efficacy of the current therapy;
 — the unsatisfactory result of treatment.
If off-label treatment is recommended, the patient 
should be informed of all the necessary components, in 
detail, before consent is obtained. According to Article 
9 of the Act on Patient Rights and the Patient Rights 
Ombudsman (UPP) [9], the patient has the right to be 
informed about his or her health, as well as to obtain 
information on the proposed and possible methods of 
treatment. The patient only has the right to agree to the 
provision of health services after obtaining the relevant 
information. The form of consent depends on the nature 
of the health service being provided. Written consent is 
required in the case of a health service posing an incre-
ased risk to the patient.
In other cases, consent may be provided orally or 
comprehensively, i.e. through such behaviour of the 
patient that sufficiently expresses his or her intention to 
undergo a specific therapeutic activity. Whether or not the 
off-label treatment of a patient with a medication poses 
an increased risk to the patient cannot be clearly stated. 
The level of risk of a given procedure can only be assessed 
subjectively, i.e. with respect to a given case, taking into 
account the level of technical complexity of the treatment, 
the patient’s physical and mental condition, and the 
experience of the medical staff. The scope and manner of 
providing information should depend on the result of this 
assessment [10]. The off-label use of drugs by a doctor 
should be based on current medical knowledge enabling 
the assessment of the risks related to such treatment. 
Simultaneously, appropriate standards of health services 
should be maintained, because, according to Article 6, 
para. 1 and Article 8 of UPP, the patient has the right to 
health services that meet the requirements of current 
medical knowledge and the assurance that the health 
services are provided with due care.
The mere consent of the patient for off-label treatment 
is not equivalent to releasing the doctor from liability for the 
prescribed medications. The limits of liability are defined 
by the previously mentioned criteria of current medical 
knowledge and due care. If the doctor does not act on 
the basis of these criteria, or fails to meet the information 
obligation and does not receive the appropriate consent 
for treatment, he or she exposes themselves to civil, cri-
minal and disciplinary liability. Some consequences are 
also associated with the financing of off-label indications 
in drug programmes [11].
Therefore, care must be taken with the off-label use of 
drugs, which must be based on reliable scientific sources. 
In the case of legal proceedings, it is the doctor’s responsi-
bility to present evidence that proves that the use of drugs 
outside the indications in the SPC was in compliance with 
current medical knowledge.
[3]. This indicates that the doctor should comply with the 
SPC when prescribing a specific therapy, although it must 
also be based on the requirements of current medical 
knowledge. Therefore, in some cases, most often in pae-
diatrics and oncology, in the absence of regulations arising 
from the SPC, the doctor may decide to use the medicine 
in a manner that differs from that specified in the SPC.
Experiment or established practice?
It is worth mentioning that, in the light of the provisions of 
the Act on the Professions of Doctor and Dentist, the justi-
fied off-label use of medicines is not so much the doctor’s 
right as his or her duty. This is because the lawmakers do 
not allow the doctor to withdraw from treatment because 
of inconsistency between current medical knowledge and 
the drug’s registration status. However, this differs from 
a therapeutic experiment [4]. On the one hand, the said 
act on the medical professions requires the doctor to act 
on the basis of the available measures, while on the other, 
Article 21, para. 2 indicates that a therapeutic experiment 
is the introduction by the doctor of new or only partially tried 
diagnostic, therapeutic or prophylactic methods in order to 
achieve a direct health benefit for the person being treated. 
Conducting an experiment involves increased requirements, 
such as the need to obtain the consent of the Ethics Com-
mittee. The automatic qualification of the off-label use of 
a medicine as a therapeutic experiment is controversial, 
although this view was once shared by the National Health 
Fund in the financing of medicines [5]. From the definition of 
a medical experiment, it can be deduced that not every use 
of an off-label drug will have its novel nature, so the position 
that any use of the drug other than one characterized in SPC 
is a medical experiment, should be rejected.
However, in its judgment of 24 November 2011, the 
Supreme Court clearly held that, when making therapeutic 
decisions, the doctor is responsible for them, so he or she 
cannot be bound by the dosage method expressed in the 
SPC. The selection of the appropriate dosage regimen must 
address the individual needs of the patient [6]. Otherwise, 
the ability of the doctor issuing the prescription, as expres-
sed in the Regulation of the Minister of Health on prescrip-
tions, to specify the dosage, would not make sense [7].
Criteria for off-label use  
and the doctor’s responsibility
In the absence of clear limits on off-label use, several 
criteria can be applied if the indication is not contained in 
the SPC. These include [8]:
 — the need to save the patient’s life or health;
 — the use of all available medicinal products registered 
in a given indication during the treatment process;
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Reimbursement of off-label use
The legal issues related to the reimbursement of medici-
nes in Poland are contained in the Polish Reimbursement 
Act [12]. The general rule is that the reimbursement in-
dications arise from the indications specified during the 
marketing authorisation procedure. The prerequisite for 
reimbursement is that the medicinal product in question is 
authorised on the Polish market [13]. However, there may 
be derogations from this rule. According to the teleological 
interpretation, the scope of reimbursement should be in 
line with the state of current medical knowledge, which 
does not necessarily have to be identical with registered 
indications. Therefore, many products are currently publicly 
financed on an off-label basis, which is often due to the 
fact that these products were reimbursed before the Polish 
Reimbursement Act came into force, and their reimburse-
ment status from before 1 January 2012 was transferred 
to the new system unchanged. Also, the practice of reim-
bursing drugs available in pharmacies, or in a catalogue 
of chemotherapy, or in drug programmes, does not always 
correspond to the registration indications.
In addition to the above practical examples of off-label 
reimbursement, the Polish Reimbursement Act provides for 
a formal procedure for the general (non-individual) public 
financing of medicines in indications other than those 
arising from the marketing authorisation, if it is necessary 
to save the lives or health of patients, where there are 
no other appropriate medical procedures financed with 
public funds.
The Polish Reimbursement Act explicitly specifies the 
ability to finance a medicinal product which has clinical 
data on its indications for use or dosage, or method of ad-
ministration, which differ from those specified in the SPC. 
Such an exceptional procedure only applies under certain 
circumstances, which are strictly defined in Article 40 of 
the Polish Reimbursement Act. According to this provision, 
the Minister of Health may issue a positive administrative 
reimbursement decision for a medicinal product with clini-
cal data, indications, dosage or means of administration 
other than those defined in the SPC should it be necessary 
to save the lives or health of patients, in the absence of 
other medical procedures financed with public funds which 
can be applied in a given clinical condition, after consulting 
the Transparency Council and the national consultant in 
the relevant field of medicine.
Therefore, a reimbursement decision issued for off-
-label indications may only differ from sections 4.1 and 
4.2 of the SPC. Most frequently, off-label reimbursement 
will apply to the extension of the population to include 
paediatrics or the addition of an indication justified by 
current medical knowledge [14].
This unique procedure is not only an exception to this 
rule regarding binding registration and reimbursement 
indications, but is also an exception to the general prin-
ciple of issuing reimbursement decisions on request. 
While the regular reimbursement procedure is initiated 
by the MAH or its representative, the off-label procedure 
may take place ex officio [8]. Furthermore, the procedure 
of issuing an off-label reimbursement decision does not 
include a stage of negotiations with the Economic Com-
mission. However, the key element is the opinion of the 
Transparency Council and of the national consultant in the 
relevant field of medicine. Although these positions are 
not legally binding on the Minister of Health, in practice 
the opinion of the consultant seems to be of crucial impor-
tance in the justification — in the light of the principles of 
evidence-based medicine — of the use of a given product 
in a specific off-label indication.
Additionally, the medicine in question should be cost-
-effective and should meet the so-called reimbursement 
criteria referred to in Article 12, items 4–6, 9, 10, 12 and 
13 of the Polish Reimbursement Act (clinical and practical 
efficacy; safety of administration; relationship between 
health benefits and risks of administration; impact on 
expenditures of the entity responsible for financing bene-
fits with public funds and the beneficiaries; existence of 
alternative medical technology in the meaning of the Act 
on Benefits and its clinical efficacy and safety of admini-
stration; health priorities; and the cost of obtaining an 
additional year of life).
The need to introduce this unique procedure into the 
Polish healthcare system, namely off-label reimbursement, 
primarily arises from therapeutic practice in paediatrics 
and oncology, which, to a significant extent, is based on 
off-label treatment [14].
Off-label reimbursement will also play a particularly 
important role in the cases of rare and extremely rare 
diseases, where the population is so small that conduc-
ting clinical trials for a given disease unit would be cost-
-inefficient.
Summary
The use of off-label medicines is important in practice, 
because, in many areas, such as paediatrics and onco-
logy, there is a shortage of medicines that can be used in 
accordance with the SPC. Following the principle of current 
medical knowledge, a doctor often goes outside the scope 
of the SPC. Therefore, it appears to be necessary to preci-
sely define the limits of off-label use. The regulation itself 
arising from Article 40 of the Polish Reimbursement Act is 
exceptional, and strictly applies to the financing process. 
The whole issue of using off-label drugs is definitely of 
a broader scope. Nevertheless, doctors should primarily 
consider the patient’s life and health, meaning that they 
should be guided by current medical knowledge and due 
care when recommending treatment.
191www.journals.viamedica.pl/folia_cardiologica
Zuzanna Chromiec, Ewa Hoffmann, Off-label use: application and reimbursement
Streszczenie
Pozarejestracyjne zastosowania leków (off-label) jest jednym z ważniejszych elementów pracy lekarzy, a niestety wciąż 
budzi wiele kontrowersji i wątpliwości. Wynika to z braku jednoznacznych, szczegółowych regulacji prawnych w tym za-
kresie. Z jednej strony lekarze powinni się kierować sposobem dawkowania i wskazaniami do stosowania określonymi 
w charakterystyce produktu leczniczego (ChPL), zaś z drugiej strony w przypadku niektórych pacjentów, w szczególności 
w dziedzinie pediatrii i onkologii, może brakować terapii, które byłyby scharakteryzowane pod kątem takiego zastoso-
wania w ChPL. Podczas przepisywania terapii off-label lekarze muszą się przede wszystkim kierować wskazaniami 
aktualnej wiedzy medycznej oraz należytą starannością. Mimo braku regulacji prawnych można wyróżnić kilka kryteriów, 
które uzasadniają zastosowanie leków off-label, na przykład konieczność ratowania życia pacjenta czy niesatysfakcjo-
nujący wynik zaleconej dotychczas terapii. Przed przepisaniem określonego leku należy poinformować pacjenta między 
innymi o ryzyku związanym z pozarejestracyjnym zastosowaniem leku. Dopiero po właściwym poinformowaniu pacjenta 
można od niego odebrać świadomą zgodę na leczenie. Niespełnienie tych obowiązków przez lekarza może go narazić 
na odpowiedzialność cywilną, karną lub dyscyplinarną. W polskim prawie przewidziano także możliwość publicznego 
sfinansowania terapii prowadzonej w innych niż wynikające z ChPL wskazaniach. Chociaż wymaga to spełnienia ustawo-
wych przesłanek, często stanowi kluczową szansę dla rzeczywistego rozpoczęcia leczenia pacjenta.
Słowa kluczowe: pozarejestracyjne stosowanie leków, off-label, zgoda pacjenta, refundacja leków
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